Myriad Genetics (Myriad Genetics) Long-Term Capital Lease Obligation : $97.4 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Long-Term Capital Lease Obligation?

Myriad Genetics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $97.4 Mil.

Myriad Genetics's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($148.4 Mil) to Sep. 2023 ($145.1 Mil) and declined from Sep. 2023 ($145.1 Mil) to Dec. 2023 ($97.4 Mil).

Myriad Genetics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($79.3 Mil) to Dec. 2022 ($130.9 Mil) but then declined from Dec. 2022 ($130.9 Mil) to Dec. 2023 ($97.4 Mil).

Myriad Genetics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Myriad Genetics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Long-Term Capital Lease Obligation Chart

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

56.90

79.30

130.90

97.40

Myriad Genetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															130.90	146.50	148.40	145.10	97.40

Myriad Genetics (NAS:MYGN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Myriad Genetics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (Myriad Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

NEO VCYT TWST GH LAB OPK NEOG FLGT CSTL CDNA TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart	officer: Executive VP Human Resources	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury	officer: Senior V.P. - Research	320 WAKARA WAY, SALT LAKE CITY UT 84108